Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.26.3
Segment Information
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information

7. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

 

The CODM, who is the Chief Executive Officer (“CEO”), President, and Chairman of the Board, manages and allocates resources to the operations of the Company on an entity-wide basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on an entity-wide basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 

 

Given the Company’s September 2025 strategic pivot to prioritize the development and distribution of Tome skincare products, the segment information disclosure has been recast for all periods presented to reflect this change. The following table summarizes the segment’s financial information including the Company’s significant segment expenses:

 

    2026     2025     2026     2025  
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2026     2025     2026     2025  
Net sales   $ 74,137     $ -     $ 74,137     $ -  
Cost of sales     (34,008 )     -       (34,008 )     -  
Gross profit     40,129       -       40,129       -  
Operating expenses:                                
Research and development                                
Clinical     -       -       78,263       705,645  
Chemistry, manufacturing and controls and nonclinical     35,811       36,274       96,068       320,104  
Personnel related     107,483       468,113       565,250       1,377,614  
Total research and development     143,294       504,387       739,581       2,403,363  
Selling, general and administrative                                
Compliance     409,501       344,290       1,541,650       1,472,750  
Legal     926,945       107,694       2,030,000       453,897  
Marketing     545,178       472,940       1,444,241       472,940  
Commercial readiness     113,852       -       242,799       -  
Personnel related     759,858       331,360       1,840,306       1,070,255  
Total selling, general and administrative     2,755,334       1,256,284       7,098,996       3,469,842  
Interest income     37,099       68,682       162,279       176,536  
Net loss   $ (2,821,400 )   $ (1,691,989 )   $ (7,636,169 )   $ (5,696,669 )